USPTO serial 85156436
ANAPHORE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- PINO, BRIAN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ANAPHORE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Noel K. Egnatios, Esq.
NOEL K. EGNATIOS, ESQ. COOLEY LLP777 6TH ST NW STE 1100WASHINGTON, DC 20001-3706UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical compositions and preparations for use in therapeutics for human, animal and livestock diseases, namely, use for cardiovascular disease, metabolic disease, autoimmune disease, diabetes, obesity, inflammatory disease, vascular disease, dermatological disease, ocular disease, hematological disease, neurological disease, gastrointestinal disease, respiratory disease, viral and infectious disease, cancer, allergies, allograft rejection, genetic disorders, diseases of the musculoskeletal and nervous system, analgesics and wound healing; pharmaceutical compositions and preparations for the diagnosis, prophylaxis and treatment of human, animal and livestock diseases, namely, cardiovascular disease, metabolic disease, autoimmune disease, diabetes, obesity, inflammatory disease, vascular disease, dermatological disease, ocular disease, hematological disease, neurological disease, gastrointestinal disease, respiratory disease, viral and infectious disease, cancer, allergies, allograft rejection, genetic disorders, diseases of the musculoskeletal and nervous system, analgesics and wound healing; vaccines; pharmaceutical compositions and preparations in the nature of contrast media for use with medical imaging equipment; biological reagents for use in clinical medical and non-clinical medical tests for the diagnosis and measurement of disease progression in human, animal and livestock diseases; biological reagents for use in clinical medical and non-clinical medical imaging | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 7, 2013 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 7, 2013 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 12, 2012 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 11, 2012 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 8, 2012 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 15, 2012 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 15, 2012 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 12, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 10, 2011 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 10, 2011 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 10, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 7, 2011 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 12, 2011 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 12, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 8, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 7, 2011 | ALIE | ASSIGNED TO LIE | — |
| Feb 9, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 9, 2011 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 9, 2011 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 9, 2011 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 9, 2011 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 28, 2011 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 27, 2010 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Oct 26, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 22, 2010 | NWAP | NEW APPLICATION ENTERED | — |